

**Delivering New Treatments,
Creating Future Smiles**



We strive to improve human health and contribute to a society enriched by smiles.

Delivering New Treatments, Creating Future Smiles

Medicine keeps advancing, but many people around the world still suffer from diseases with no cure. Under these circumstances, an innovative new drug can bring courage for tomorrow to many patients and their families, and also to every healthcare professional who wants to provide the very best treatment. That's what drives us to pioneer new methods, work across disciplines, and bring together all of our strengths. Our aim is to offer courage and strength to all who are waiting for new treatments. Our hope is that every day will continue to be vibrant and healthy for everyone for years to come. Creating a future filled with smiles for all. This is our goal at Taiho Pharmaceutical.


Taiho Pharmaceutical is making diverse contributions to sustainability, always working for better health and more smiles for people around the world.





Taiho Pharmaceutical in Numbers

Taiho Pharmaceutical works hard every day to support people's health and bring more smiles to the world. The figures here illustrate the uniqueness of Taiho Pharmaceutical's businesses and strengths as a company.



Countries Where LONSURF
Has Been Approved

100 Countries and Regions

(as of Dec. 2022)

LONSURF, a drug discovered by Taiho Pharmaceutical, was launched in 2014 as a treatment for colorectal cancer. It has been approved in 100 countries and regions around the world. In 2019, an additional indication for gastric cancer was obtained in Japan, the U.S., and Europe, and this indication has now been approved in 85 countries and regions worldwide.

Sales of Tiovita Drink Series

Approx. **143,000,000**
Bottles/Year (2022)

Tiovita Drink is a nutritive energy drink which represents the company's Consumer Healthcare Business. A long-seller since 1964, the Tiovita series sells approximately 143 million bottles per year, for a cumulative total of more than 6.7 billion bottles over the years.



R&D Expenses to Net Sales

41.4% (2022)

Taiho Pharmaceutical focuses on in-house drug discovery. In its ongoing pursuit of research and development of innovative new drugs that can support people's health worldwide, the company leverages its network of research institutions, which goes beyond Japan to include the U.S., Europe, and other parts of Asia.

Note: R&D expenses to net sales stood at 29.4% for 2021. The figure was exceptionally high for 2022 due to a temporary increase in R&D expenses resulting from intellectual property (IP) acquisition.

Percentage of Employees Taking Childcare Leave

Women **96%** Men **107%** (2022)

With the amendment of Japan's Act on Childcare Leave and Caregiver Leave, more men are taking childcare leave at an early stage after childbirth. Taiho Pharmaceutical provides support for employees to balance work with childcare. This includes interviews related to childcare and making available an on-site daycare center.

Notes : Calculated with the number of employees who gave birth to a child in 2022 as the denominator, and the number of employees who started parental leave as the numerator. Although calculated at 96% using the above method, all women who gave birth took childcare leave. For men, the figure includes those who took a short period of childcare leave.



Pioneering Oral Anticancer Drugs

Since **1974**

In 1974, Taiho Pharmaceutical launched an oral anticancer drug, when they were still uncommon. Since then, the company has launched a series of oral anticancer drugs developed in-house. In recent years, the company has been conducting innovative drug research and development using novel platform technologies, yielding numerous new drug candidates, primarily in oral formulations.



Oncology Products

71.3% of Sales (2022)

Oncology products account for a large proportion of Taiho Pharmaceutical's sales: 71.3% of ¥139.3 billion. While taking on the challenge of creating anticancer drugs with diverse mechanisms of action leveraging its strengths in oncology, Taiho Pharmaceutical also works on developing novel drugs in the fields of allergy/immunology and urology.

History of Taiho Pharmaceutical

Taiho Pharmaceutical has been in the business of pharmaceuticals (prescription drugs), including anticancer drugs, since its early days in the 1960s. Beginning with Tiovita Drink, its business also includes consumer healthcare products that can be purchased at pharmacies and drug stores. All along, Taiho Pharmaceutical has focused on these two businesses, both closely connected to people's health and smiles.

Leveraging extensive evidence and a wealth of experience gained over half a century of anticancer drug development, Taiho Pharmaceutical will continue to develop new drugs that contribute to patients with cancer around the world.

History of Pharmaceutical Business (Anticancer Drug Development)

Encountering Futraful: The Beginning of Our Anticancer Drug Development

In 1969, Taiho Pharmaceutical's first president, Yukio Kobayashi, visited the former Soviet Union for business discussions. While there, he encountered a novel chemical compound, a derivative* of 5-fluorouracil (5-FU). Kobayashi sensed its great potential. He instantly decided to conduct clinical trials in Japan, and the company succeeded in development after overcoming many hurdles. In 1974, the oral anticancer drug Futraful, which enabled oral administration, was developed together with an injectable. Oral Futraful enabled outpatient therapy, which later led to the establishment of the concept of adjuvant chemotherapy.

*Derivative: A compound created by a change in part of a molecule of a given compound.

1969 Yukio Kobayashi shaking hands with Futraful developer



1974 Futraful capsule and Futraful injection launched in Japan



Pursuing the Advancement of Anticancer Drugs: Overcoming Various Challenges

Pursuing the efficiency of Futraful, further research led to the launch of combination drugs in Japan: UFT in 1984 and TS-1 in 1999.

1999 TS-1 combination capsule launched in Japan



1980

Delivering Innovative Drugs from Japan: Making a Difference in 100 Countries and Regions Worldwide

Entering the 21st century, Taiho Pharmaceutical stepped up its global in-house development of new drugs that can contribute to cancer treatment. This led to the launch of LONSURF, an oral anticancer drug discovered in-house, in Japan in 2014. The following year, LONSURF received approval to be marketed in the U.S., becoming the first product the company itself sold in the U.S. market. In 2016, it was approved by the European Commission, and it continues to spread around the world.

2000



2014 LONSURF combination tablet launched in Japan

2023



2022 Jeselhy tablet launched in Japan

Committed to Addressing Unmet Medical Needs

Taiho Pharmaceutical is actively engaged in drug discovery for rare and intractable diseases. In 2022, the company launched Jeselhy tablets, a treatment for gastrointestinal stromal tumor (GIST), demonstrating its commitment to addressing areas with high unmet medical needs.

Pioneering the Future of Cancer Treatment: Continuing to Improve Patients' Quality of Life

In 2013, Taiho Pharmaceutical launched TS-1 as the world's first anticancer agent in orally disintegrating (OD) tablet form. This helps to improve the quality of life of patients since it can be taken with or without water. Taiho Pharmaceutical has also launched products designed to offer comprehensive care in oncology, including cancer supportive care, such as antiemetic agents.

History of the Consumer Healthcare Business

Taiho Pharmaceutical meets people's needs and supports healthy, fulfilling lifestyles with products such as the Tiovita series, the Solmack series, and Harnicare.



2001

Harnicare, an herbal medicine for mild incontinence and frequent urination, launched in Japan

To meet the needs of an aging society, Harnicare was developed as an herbal medicine that ameliorates urinary problems in an easy-to-take liquid formulation. It is the first OTC drug in Japan to be approved for the treatment of mild incontinence.

1979 Solmack, an herbal digestive support drink, launched in Japan

Solmack was introduced as a liquid gastrointestinal medicine containing herbal drugs. With the convenience of being able to drink straight from the bottle, Solmack has been a choice for over 40 years.



1964 Tiovita Drink launched in Japan

Tiovita Drink was created as a drink to support health in daily life. It contains ingredients such as taurine and B vitamins which help people recover from tiredness. Turned into a series, the expanded lineup today sells approximately 143 million bottles per year, for a cumulative total of more than 6.7 billion bottles delivered to consumers over the years.

1960

1980



2000



2018 Efil, a virus removal/antibacterial spray, launched in Japan

Efil is a virus removal and antibacterial spray that utilizes the antibacterial, antiviral, and deodorizing effects of metal ions.

2017 PITAS Sore Throat Troche launched in Japan

The PITAS series of film-type troches was developed by listening to the requests of office workers. The round film-type troche containing the medication sticks to the roof of the mouth to relieve problems such as sore throat, swelling, coughing, and bad breath. The product is thin, easy to carry, and can be used while speaking without being noticed by others, making it convenient in business situations such as important meetings and when communicating with customers. In 2022, PITAS series was also launched in Singapore.



2021 BUP-4 LADY launched in Japan

It is estimated that about 8 million Japanese men and women over 40 years old suffer from symptoms of an overactive bladder. To address this problem, which affects the quality of daily life, BUP-4 LADY was launched as Japan's first OTC drug indicated for urinary urgency in women and is available for purchase at pharmacies under the guidance of a pharmacist.



2023



2018 Taiho Pharmaceutical's official online shop launched in Japan

Taiho Pharmaceutical launched an e-commerce business for its products. It sells preventative healthcare products such as Femilacto, a supplement containing *lactobacillus* Rosell-11 & 52 to care for women's bodies.

Please refer to each product's brand site for its precautions for use.

Looking toward expansion in other ASEAN countries in addition to Singapore, Taiho Pharmaceutical will continue to research and develop new and unique products that meet people's needs and enrich their lives, hoping to keep people smiling longer.

Taiho Pharmaceutical's Strengths

Drug Discovery

One of Taiho Pharmaceutical's great strengths is its ability to create innovative new drugs using its unique drug-discovery platforms. Within the Otsuka Group, Taiho Pharmaceutical has an important role in oncology and takes on the challenge of creating therapeutics for significant unmet needs such as cancers with brain metastasis and those with RAS mutations. The company is also advancing drug-discovery research in the area of allergy/immunology by applying technologies emerging from its cancer research. In addition, Taiho Pharmaceutical is pursuing external research collaboration in and outside Japan and has built its own network with biotech ventures and academia (universities and research institutions) to obtain innovative drug-discovery technologies and drug seeds, in order to supplement its own technologies and accelerate R&D.

Percentage of In-house Drug Discovery in Taiho Pharmaceutical's Pipeline

(as of December 2022)

Approx. **82%**

Compounds in development 17

Drugs discovered in-house 14 (approx. 82%)


Oncology compounds 11



Learn more
about Taiho
Pharmaceutical's
product pipeline



Creating Innovative New Drugs



Creating New Drug Candidates: With Close Collaboration and Using World-Class Drug-Discovery Platforms

The driver of Taiho Pharmaceutical's high percentage of in-house drug discovery is the close collaboration among its departments and researchers, which together represent extensive knowledge and experience in their specialties. The company has also focused on developing and expanding drug-discovery platform technologies, such as its own unique Cysteinomix Drug Discovery Platform, which has gained international recognition. Employing these technologies, Taiho Pharmaceutical has succeeded in creating an abundant development pipeline, including futibatinib, which was approved for marketing in the United States in 2022.

Leveraging External Collaboration to Accelerate R&D: Meeting the Needs of Patients Awaiting New Drugs

Taiho Pharmaceutical develops strategic alliances with external partners to enhance its R&D capabilities, seeking to deliver new drugs to patients suffering from diseases with no effective treatment. The company works with an R&D network in Japan as well as Otsuka group companies, other pharmaceutical companies, and academia in the U.S., Europe, and Asia to supplement its own technologies and development pipeline and to speed up research and development.

Supporting and Collaborating with Biotech Ventures: Expanding the Potential for Future New Drugs

Taiho Pharmaceutical's corporate venture capital firms, Taiho Ventures, LLC (established in 2016), and Taiho Innovations, LLC (established in 2019), invest in and support biotech ventures and startups around the world that are engaged in innovative new drug R&D. They aim to gain new perspectives and ideas and create innovations that will expand the potential for the new drugs of the future by accessing original drug-discovery technologies and seeds in invested companies and networks.

Employee Voice



**Shinji Mizuarai,
Ph.D., MBA**

Head, Discovery and
Preclinical Research
Division

Overcoming High Hurdles in the Constant Pursuit of Drug Discovery to Contribute to Better Treatment

Molecular targeted drugs we discovered in our research center have been approved for marketing after going through clinical trials and are beginning to reach patients with cancer who are awaiting new treatments. Inspired by the confidence and joy this brings, we will continue to tackle intractable cancers and other challenging medical needs that present serious drug discovery hurdles. This is why we are strengthening our research capabilities and actively working with internal and external partners, academia, other pharmaceutical companies, and biotech ventures, to further propel our drug discovery.



Learn more
about drug
discovery



Taiho Pharmaceutical's Strengths

Human Resources

Handling pharmaceuticals means coming face to face with life itself. Taiho Pharmaceutical's basic policy is, "Drug making starts with developing people." The company aims to develop human resources with a high sense of ethics and multifaceted sensibilities, people with knowledge of pharmaceuticals and skills in business execution who are ready to take on new challenges boldly. By offering new employee training and other diverse educational programs, the company provides a rich curriculum that includes opportunities for employees to develop their self-awareness as contributors to a company closely involved with human life, as well as to acquire professional expertise and improve their communication skills. The company also provides programs to equip personnel with digital transformation skills.

Systems Supporting Taiho Pharmaceutical's Human Resources

Master MRs*—internally certified MRs

(as of January 2023) *MR: Medical Representative

167

Academic Experts
10

Correspondence course fee support system

(subsidizes 70% of course fees)

Used by
approx.

500 employees
annually

Earning Trust in Medical Settings: Developing MRs With a Positive Approach to Life

<p>Internal certification system</p>	<p>In order to develop human resources capable of providing and gathering the latest treatment information to and from medical professionals, Taiho Pharmaceutical conducts internal certifications every year in two categories — Master MRs, who combine knowledge about cancer with the ability to make proposals from the patient's point of view, and Academic Experts, who have a broad understanding of disease and treatment.</p>	<p>TAIHO Mentorship Program</p>	<p>The Mentorship Program encourages the growth of young MRs using the skills and mature mindsets of experienced senior MRs. The program allows young MRs to accompany senior MRs beyond the branch where they are assigned. Learning the practical skills and creative methods of senior MRs leads to higher motivation among young MRs.</p>
--------------------------------------	---	---------------------------------	---

Diverse Programs to Develop Global Leaders

As Taiho Pharmaceutical actively expands its business globally, it is focusing on educating human resources ready to flexibly solve cross-border problems in cooperation with partners outside Japan. The company supports the systematic development of these leaders by providing opportunities for "cross-border and cross-division work experiences" and "various training programs to hone the skills and mindset needed in global leaders" to members of each generation with strong aspirations to excel globally.

<p>Work experiences to broaden perspectives</p>	<ul style="list-style-type: none"> ● Job rotations ● Dispatch to group companies outside Japan ● Global business experience in Japan, etc.
<p>Training of global leaders</p>	<ul style="list-style-type: none"> ● Intercultural communication workshops ● Cross-border external training* ● One-on-one dialogues with executives, etc. <p>*Training designed to foster new perspectives by immersing oneself in a completely different environment</p>

Inspiring the Desire for Growth: Diverse Career Development Support Systems

To support employees' desire to grow, companies must provide them with opportunities to think freely about their future vision. Taiho Pharmaceutical uses career design sheets and holds career design seminars and career workshops in which employees participate freely. Meanwhile, the company encourages employees to openly discuss their careers five to ten years into the future with their supervisors. It also provides opportunities for career consultation by qualified in-house career counselors and has put in place support systems for correspondence courses and for obtaining qualifications to support growth.

Employee Voice

As an in-house career counselor, I support employees who wish to explore their careers and understand themselves.



Akiko Shimizu
Human Resources

Conducting career training and offering individual consultations in the career counseling office, I try to support each employee to explore his or her future career vision. Together, we consider changes in the environment and make plans so each person can keep growing professionally throughout the decades. I always strive to foster an open culture where people can discuss their vision for the future with their supervisors and colleagues, and I help employees build careers that not only contribute to the organization but also provide a sense of accomplishment.

GLOBALIZATION

Taiho Pharmaceutical's Future

Taiho Pharmaceutical is expanding its global reach, looking to become a specialty pharma trusted worldwide. The company conducts drug discovery R&D in collaboration with group companies in the U.S., Europe, and Asia. With bases in 16 countries worldwide, it is building its own marketing structures and expanding its sales network. In 2022, the percentage of the company's sales originating outside Japan grew to about 38%. In recent years, the company has established two corporate venture capital firms in order to expand its development pipeline and create innovation. Taiho Pharmaceutical aspires to make even greater contributions to medical care worldwide.



Message from EUROPE

Properly delivering Taiho Pharmaceutical's new drugs to patients in Europe

Atsushi Azuma, Ph.D.

Chairman
TAIHO ONCOLOGY EUROPE GMBH



Established in January 2021 as a marketing company in Europe for the Taiho group, Taiho Oncology Europe is collaborating with other Taiho group companies to build its own sales/marketing organization for the launch of the novel oral anti-cancer agent futibatinib (development code: TAS-120), an FGFR inhibitor. Going forward, we hope to contribute to health and smiles for patients in Europe by promoting the proper use of our drugs and further expanding our lineup of anticancer drugs while strengthening our organization.

Message from ASIA

Aiming to deliver innovative new drugs to as many people in Asia as possible

Yoshimasa Nishimura

Managing Director
TAIHO PHARMA ASIA PACIFIC PTE. LTD.



Taiho Pharmaceutical of Beijing and Taiho Pharma Asia Pacific share the slogan, "By Local. For Local." Our primary mission is to provide the innovative new drugs and unique consumer healthcare products developed by Taiho Pharmaceutical to medical professionals, to patients, and to all the people of Asian countries and regions, through the caring hands of our local employees. Our entire team is united to give our best effort every day to bring smiles to the faces of as many locals as possible.

Message from NORTH AMERICA

Transforming the company while working to improve human health one patient at a time

Timothy Whitten

President & CEO
TAIHO ONCOLOGY, INC.



Taiho Oncology is poised to have a transformative year in 2023 and will take several big leaps during the year. Those leaps are all focused on improving the lives of patients with cancer, their families and their caregivers. We will do this with new indications for existing products, expanding our reach geographically and investing and advancing our compounds in the clinic. Taiho Oncology looks forward to collaborating with our Taiho colleagues to improve health and create more smiles for people around the world.



SUSTAINABILITY

Taiho Pharmaceutical's Future

Taiho Pharmaceutical's corporate philosophy, "We strive to improve human health and contribute to a society enriched by smiles," is the company's unchanging guideline for the future. Taiho Pharmaceutical's CSR mission is designed to ensure that the company's business activities help solve social and environmental issues. The company is working hard to help achieve the Sustainable Development Goals (SDGs) while promoting employee health, pursuing diversity and inclusion, and practicing optimal governance.

CSR Mission

As a member of the Otsuka group, Taiho Pharmaceutical has integrated CSR into its businesses and aims to achieve its own sustainable growth as well as healthy and sustainable societies enriched by smiles, in line with its corporate philosophy. We pursue these objectives supported by a comprehensive governance system.



Healthier Society (Society)

Health
People
Quality in All We Do



Healthier Planet (Environment)

Carbon Neutrality
Circular Economy
Water Neutrality



Healthier Company (Governance)

Corporate Governance
Compliance
Risk Management

Taiho Pharmaceutical's Materiality (Material Issues) and Related SDGs

Taiho Pharmaceutical is committed to doing its part in achieving the SDGs. As a company in the field of medical care, the company is focusing on the health and welfare-related targets. Meanwhile, it also aims to make broader social contributions and deliver business growth by helping to address social issues such as consideration for human rights and the environment. Here are some key objectives and achievements.



- Addressing unmet medical needs by strengthening versatile drug discovery capabilities
- Addressing medical needs related to patients with cancer by improving access to information and treatment



- Endorsing the Women's Empowerment Principles (WEPs) as a member of the Otsuka Group



- Establishing goals for effective water resource use

KPI Expand the plant water management program to all locations in Japan



- Providing systems, environment, and education to allow employees with cancer and other illnesses to work while receiving treatment



- Establishing goals regarding waste

KPI Simple Incineration/Landfill
50% reduction by 2028 as compared to 2019



- Formulating an Otsuka group-wide procurement policy cognizant of human rights, labor, the environment, anti-corruption, etc.



- Establishing goals to reduce greenhouse gas emissions

KPI Greenhouse Gas Emissions
50% reduction by 2028 as compared to 2017



- Integrating Japan-based drug discovery and global open innovation



- Compliance programs and compliance with related laws and regulations

Learn more about sustainability at Taiho Pharmaceutical



Healthcare Support Supporting People's Health in Many Ways



Taiho Smile Support: Supporting Solutions That Address Issues Related to Cancer

The Taiho Smile Support program supports crowdfunding by organizations and individuals seeking to solve various social issues related to cancer that cannot be solved by drugs alone. Matching funds are given when the target amount is reached.



Expanding Support for Patients and Caregivers in the U.S.

U.S. subsidiary Taiho Oncology collaborates with and supports patient groups in the field of oncology. The company especially focuses on supporting patients and their caregivers by conducting various awareness raising programs as well as educational and research-related activities and events.



Supporting the Establishment of a Neonatal Intensive Care Unit (NICU) in Laos

Taiho Pharma Asia Pacific, an Asian subsidiary, supported the establishment of an NICU in Khammouane, Laos, to address unmet needs in the region's health and medical sectors. The NICU, named "Taiho NICU," began operation in May 2021.



Initiatives for Sustainability

Social and Community Contribution Activities



Initiatives for Health



Supporting Employees Creating Workplaces Where Everyone Can Work with Peace of Mind

Supporting Employees Who Need to Balance Work and Treatment Needs

For employees with cancer and chronic illnesses, Taiho Pharmaceutical has established work systems to balance work and treatment needs, including accrued paid time off, extended time off, remote work, and a reemployment system that allows employees to return to work.

Health Promotion Initiatives

Taiho Pharmaceutical is working to reduce smoking among employees to zero by 2023. It provides a subsidy for smoking cessation outpatient expenses and carefully enforces internal rules to protect people from passive smoking. The company also provides an exercise app to all employees to encourage fitness habits.

Operating an On-Site Daycare Center

Taiho Pharmaceutical has established a daycare center on the leafy grounds of the Tsukuba Area. A nurse is always on-site, and dinner is also provided during extended-hours childcare. The nursery is not limited to monthly childcare; it also offers temporary childcare for the children and grandchildren of employees. Taiho Pharmaceutical will continue to provide an environment where employees who are raising children can work with peace of mind.

Taiho Pharmaceutical is also enhancing diversity and inclusion through human resource development, balancing of work with childbirth and childcare, and health support initiatives that ensure that employees are able to work with vitality.




Diversity and Inclusion



Global Standard Quality Assurance

Taiho Pharmaceutical's four plants — the main Tokushima Plant, and the Kitajima, Saitama, and Inuyama plants — work together seamlessly on production. All of these plants implement thorough quality control in compliance with GMP* standards. The Tokushima, Kitajima, and Saitama plants in particular have met international standards, as attested to by inspections by U.S. and European authorities. With a responsibility to provide a stable supply of life-sustaining medicines, Taiho Pharmaceutical also takes steps to prepare for disasters. For the supply of anticancer drugs, the company has acquired ISO 22301, an international standard for business continuity management.

*GMP: Good Manufacturing Practice is a system for ensuring that products are consistently produced and controlled according to quality standards.



Employee Voice

Hoping to bring peace of mind and smiles to patients and their families with high-quality medicines



Yukihiro Dan, Ph.D.

Director,
Product Quality Assurance
Department

I have experienced firsthand the power of medical technology and pharmaceuticals to open the door to the future, when I almost lost my child to illness. Hoping to bring happiness to as many people as possible with Taiho Pharmaceutical's products, we are determined to continue providing high-quality medicines that patients can take with peace of mind through our quality assurance work, which includes building a world-class pharmaceutical quality system and managing its operations.

Photo: Kitajima Plant Administrative Building

Main Products

Pharmaceutical Products

Learn more about pharmaceutical products



LONSURF Antitumor Agent



TS-1 Antimetabolic Agent



Jeselhy Antitumor Agent



Abraxane Antitumor Agent



Aloxi
5-HT₃ Receptor Antagonist Antiemetic Agent



Arokaris
Selective NK₁ Receptor Antagonist Antiemetic Agent



TREMFA
Human Anti-Interleukin (IL)-23p19 Monoclonal Antibody



Bilanoa
Antiallergic Agent

Consumer Healthcare Products

Learn more about consumer healthcare products



Tiovita Nutritive Energy Drink



Solmack
Herbal Digestive Support Drink



Harnicare
Herbal Medicine for Mild Incontinence and Frequent Urination



Harnicare
Bearberry Tablet
Herbal Medicine/
Urinary Tract Antiseptic



BUP-4 LADY
Overactive Bladder Medication



PITAS
Film-Type Lozenge



Efil
Virus Removal/
Antibacterial Spray



Femilacto
Food Supplement
Containing Mixed
Lactobacillus Powder

A Promise from Taiho Pharmaceutical

Today and Every Day

Nothing feels so precious as the everyday

flowing along in the usual way.

Supporting the flow of your life is our work.

When the flow of your everyday life is lost,

we put all our power into helping you restore it

—Today and Every Day.

A promise from each one of us at Taiho Pharmaceutical.

The Thoughts That Inspire Everyone at Taiho

The flow of everyday life, with its familiar scenes and rhythms, is often taken for granted. It is often when people get sick, or become worried about the state of the world or their circumstances, that they finally realize the subtle value of everyday life.

At Taiho Pharmaceutical, we want our drug discovery to go beyond curing diseases. It is also our passion to give strength and to constantly support the precious moments of everyday life, helping to keep them flowing for all people, no matter what their health condition is.

As people in a business closely involved with human life, we ask ourselves: How deeply do we think about people's lives? How well do we understand the environment surrounding patients and their families? How much can we improve patients' quality of life? By considering everything from treatment to disease prevention, we hope to contribute to better health and bring smiles to as many people as possible.

Today and Every Day

This is a promise from, and the genuine wish of, each one of us working at Taiho. This is the story behind our communication slogan.

Today and Every Day



President's Message

Building Societies Enriched by Smiles with the Power of Pharmaceuticals — Doing What Needs to Be Done

Taiho Pharmaceutical will celebrate its 60th anniversary this year. Over all these decades, our employees have each thought about what it means for Taiho Pharmaceutical to do what needs to be done, and then acted accordingly. This is what enabled us to develop a new oral anticancer drug, taking into consideration patients' quality of life at a time when such drugs, which could be taken at home, were scarcely used. Ever since, we have invested in the constant search for optimal methods of administration. Looking back on some of our history, it is clear that Taiho Pharmaceutical's growth has been supported by a culture where people persistently do what needs to be done, and passing the baton of that determination to their colleagues. We aim to keep growing by continuing to develop human resources who have the commitment and capacity to do what needs to be done.

"We...contribute to a society enriched by smiles" is a phrase that I especially value in our corporate philosophy. Working together with colleagues around the globe, our entire team will continue to deliver to the world high-quality, outstanding products that can be used with peace of mind. We will do our best to bring smiles to patients, indeed, to all people facing various problems, always helping to keep the rhythm of life flowing each and every day. I am confident that these efforts will enhance Taiho Pharmaceutical's presence as a valuable company that supports people's health and helps to build sustainable societies.

小林将之

Masayuki Kobayashi
President and Representative Director



Corporate Data

Company Name	TAIHO PHARMACEUTICAL CO., LTD.
Established	June 1, 1963
Capital	¥200 million
Representative	Masayuki Kobayashi, President and Representative Director
No. of Employees	2,170 (as of December 31, 2022)
Sales	¥139.3 billion (2022)
Net Income	¥5.1 billion (2022)
Offices	Head Office: Tokyo Branches: 8 in Japan for prescription drug sales 4 in Japan for consumer healthcare Offices: 53 in Japan Plants: 4 in Japan Laboratories: Tsukuba (Ibaraki), and Tokushima
Head Office Location	1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan TEL: +81-3-3294-4527



<https://www.taiho.co.jp/en/>




Management

President and Representative Director	Masayuki Kobayashi
Managing Director	Atsushi Azuma
Managing Director	Tatsuya Niki
Executive Director	Takeshi Sagara
Executive Director	Noriyuki Takahashi
Standing Audit & Supervisory Board Member	Nobuyuki Hashimoto
Standing Audit & Supervisory Board Member	Yasunori Okada
Outside Audit & Supervisory Board Member	Tatsuya Nakajima

(As of March 31, 2023)

Net Sales (2022)



Otsuka Group Corporate Philosophy

Otsuka-people creating new products for better health worldwide


Overview

The Otsuka group of companies, whose origins date back to 1921, aims to contribute to the health of people around the world. It aims to do so through two main pillars: the pharmaceutical business for the diagnosis and treatment of diseases and the nutraceutical^{*1} business to support the maintenance and promotion of everyday health.

The company's culture, summarized in a few words as, "Ryukan-godo" (by sweat we recognize the way), "Jissho" (actualization) and "Sozosei" (creativity), have been fostered by successive Otsuka leaders. These are emphasized by our 47,000^{*2} employees across 196 group companies in 32 countries and regions who strive to create and market unique products and services.

^{*1} Nutraceuticals: nutrition + pharmaceuticals ^{*2} As of end of December, 2022. Otsuka Holdings and subsidiaries and affiliates.

Organizational Structure




Company Name	Otsuka Holdings Co., Ltd.
Established	July 8, 2008
President and Representative Director, CEO	Tatsuo Higuchi
Capital	81.69 billion yen
Head Office	2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo
Business Description	Strategic management and oversight of the group companies, and provision of specialized business services as a holding company of the group

Financial Highlights


(FY2022)

Revenue by Business Segment
Revenue to external customers



	(JPY billion)
Pharmaceuticals	1137.9
Nutraceuticals	437.0
Consumer Products	35.9
Others	127.3

Revenue by Geographical Segment
Revenue to external customers



	(JPY billion)
Japan	654.7
North America	683.5
Europe	173.2
Others	226.6

Sustainability Mission

Address social issues such as the evolution toward a healthier and more sustainable society, while simultaneously achieving growth. These activities are all supported by a comprehensive governance system.

Contribution to a More Sustainable Society

Otsuka's business is fully synchronized with our efforts to address social issues

Otsuka-people creating new products for better health worldwide



Society (Healthier Society)
Health People Quality in all we do



Environment (Healthier Planet)
Carbon neutrality Circular economy
Water neutrality



Governance

Corporate governance Compliance Risk management







Today and Every Day

